Literature DB >> 15327518

Detection of serine 473 phosphorylated Akt in acute myeloid leukaemia blasts by flow cytometry.

Pier Luigi Tazzari1, Alessandra Cappellini, Tiziana Grafone, Irina Mantovani, Francesca Ricci, Anna Maria Billi, Emanuela Ottaviani, Roberto Conte, Giovanni Martinelli, Alberto M Martelli.   

Abstract

The phosphoinositide 3-kinase/Akt signalling pathway is a recently recognized important parameter in the prognosis and the response to treatment of acute myeloid leukaemia (AML). Akt kinase is activated by phosphorylation on Thr 308 and Ser 473. Active Akt promotes cell growth and survival to apoptotic insults. Thus, it seems important to evaluate Akt phosphorylation in AML blasts. This work aimed to establish whether it was possible to detect Akt phosphorylation on Ser 473 of AML blasts by means of flow cytometry. High levels of Akt activity and phosphorylation were detected in 13 of 15 cases of AML. Flow cytometric analysis revealed similar patterns of Ser 473 expression as was observed with Akt kinase activity and Western blot analysis of Thr 308 and Ser 473 phosphorylation. Double immunostaining enabled the simultaneous flow cytometric detection of an AML-associated antigen (CD33) and Ser 473 phosphorylated Akt in leukaemic blast populations. Our results indicate that flow cytometry enabled the rapid and quantitative assessment of Ser 473 phosphorylated Akt of AML blasts that, when used in combination with cell surface staining, can provide more accurate phenotyping of AML blasts.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15327518     DOI: 10.1111/j.1365-2141.2004.05121.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML.

Authors:  James Marvin; Suchitra Swaminathan; Geoffrey Kraker; Amy Chadburn; James Jacobberger; Charles Goolsby
Journal:  Blood       Date:  2011-01-13       Impact factor: 22.113

Review 2.  New targets for the antitumor activity of gambogic acid in hematologic malignancies.

Authors:  Li-jing Yang; Yan Chen
Journal:  Acta Pharmacol Sin       Date:  2012-12-31       Impact factor: 6.150

3.  Development of a peptidase-resistant substrate for single-cell measurement of protein kinase B activation.

Authors:  Angela Proctor; Qunzhao Wang; David S Lawrence; Nancy L Allbritton
Journal:  Anal Chem       Date:  2012-08-09       Impact factor: 6.986

4.  Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.

Authors:  Ellen Weisberg; Lolita Banerji; Renee D Wright; Rosemary Barrett; Arghya Ray; Daisy Moreno; Laurence Catley; Jingrui Jiang; Elizabeth Hall-Meyers; Maira Sauveur-Michel; Richard Stone; Ilene Galinsky; Edward Fox; Andrew L Kung; James D Griffin
Journal:  Blood       Date:  2008-01-09       Impact factor: 22.113

Review 5.  FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.

Authors:  Ellen Weisberg; Rosemary Barrett; Qingsong Liu; Richard Stone; Nathanael Gray; James D Griffin
Journal:  Drug Resist Updat       Date:  2009-05-20       Impact factor: 18.500

6.  The Paradox of Akt-mTOR Interactions.

Authors:  Lakshmipathi Vadlakonda; Abhinandita Dash; Mukesh Pasupuleti; Kotha Anil Kumar; Pallu Reddanna
Journal:  Front Oncol       Date:  2013-06-20       Impact factor: 6.244

Review 7.  The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.

Authors:  Alberto M Martelli; Camilla Evangelisti; Francesca Chiarini; James A McCubrey
Journal:  Oncotarget       Date:  2010-06

Review 8.  Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.

Authors:  Alberto M Martelli; Francesca Chiarini; Camilla Evangelisti; Alessandra Cappellini; Francesca Buontempo; Daniela Bressanin; Milena Fini; James A McCubrey
Journal:  Oncotarget       Date:  2012-04

9.  Overexpressed CISD2 has prognostic value in human gastric cancer and promotes gastric cancer cell proliferation and tumorigenesis via AKT signaling pathway.

Authors:  Lan Wang; Fei Ouyang; Xiaobo Liu; Shu Wu; Hong-Mei Wu; Yuandong Xu; Bin Wang; Jinrong Zhu; Xuehu Xu; Liang Zhang
Journal:  Oncotarget       Date:  2016-01-26

10.  Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy.

Authors:  S Z Gadhoum; N Y Madhoun; A F Abuelela; J S Merzaban
Journal:  Leukemia       Date:  2016-08-08       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.